Randomized Trial of Cisplatin versus Firocoxib versus Cisplatin/Firocoxib in Dogs with Transitional Cell Carcinoma of the Urinary Bladder
Article first published online: 3 DEC 2012
Copyright © 2012 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 27, Issue 1, pages 126–133, January/February 2013
How to Cite
Knapp, D.W., Henry, C.J., Widmer, W.R., Tan, K.M., Moore, G.E., Ramos-Vara, J.A., Lucroy, M.D., Greenberg, C.B., Greene, S.N., Abbo, A.H., Hanson, P.D., Alva, R. and Bonney, P.L. (2013), Randomized Trial of Cisplatin versus Firocoxib versus Cisplatin/Firocoxib in Dogs with Transitional Cell Carcinoma of the Urinary Bladder. Journal of Veterinary Internal Medicine, 27: 126–133. doi: 10.1111/jvim.12013
- Issue published online: 11 JAN 2013
- Article first published online: 3 DEC 2012
- Manuscript Accepted: 6 OCT 2012
- Manuscript Revised: 4 SEP 2012
- Manuscript Received: 11 APR 2012
- Merial Limited
- Bladder cancer;
- Cox inhibitor;
Cisplatin combined with a nonselective cyclooxygenase (cox) inhibitor has potent antitumor activity against transitional cell carcinoma (TCC) in dogs, but this treatment is limited by renal toxicosis. Cox-2 is expressed in TCC, but only in limited sites within the kidney. A cox-2 inhibitor could enhance the antitumor activity of cisplatin with potentially fewer adverse effects on the kidney.
Cisplatin/cox-2 inhibitor treatment will have greater antitumor activity but no more renal toxicosis than cisplatin alone in dogs with TCC.
Forty-four dogs with naturally occurring urinary bladder TCC.
Dogs were randomized to receive cisplatin (60 mg/m2 IV q21d), firocoxib (5 mg/kg PO q24h), or the combination. Tumor measurements were determined before and at 6-week intervals during treatment. Renal function was monitored by serum creatinine concentration, iohexol clearance, and urine specific gravity. Toxicoses were graded according to Veterinary Co-Operative Oncology Group (VCOG) criteria.
The remission rate with cisplatin/firocoxib (57%) was significantly (P = .021) higher than that with cisplatin alone (13%). Renal and gastrointestinal toxicoses were common in dogs receiving cisplatin, but there were no significant differences between dogs receiving cisplatin or cisplatin/firocoxib. Firocoxib alone induced partial remission or stable disease in 20 and 33% of dogs, respectively.
Firocoxib significantly enhanced the antitumor activity of cisplatin resulting in partial remission in more than half of the cases. The toxicoses inherent to cisplatin, however, were noted in dogs receiving this combination. Firocoxib had antitumor effects as a single agent and can be considered a palliative treatment for dogs with TCC.